title: [Malignant lymphoma: magnetic resonance tomography findings in residual supradiaphragmatic space-occupying lesions].
abstract: OBJECTIVE
  Evaluation of MR imaging in patients with Hodgkin's lymphoma and high grade non-Hodgkin's-lymphoma and mediastinal residual mass after first line chemotherapy.
  
  
  METHODS
  MR imaging (1.5 T) was performed in 36 patients (Hodgkin's lymphoma n = 26, NHL n = 10) after first line chemotherapy). Twenty patients had inactive residual mass, 16 patients had residual lymphoproliferative lesions. T1- and T2-weighted spin echo images were visually analysed by a score index (range 1-5) as well as quantification of enhancement by signal-intensity-ratios SImax/SIplain).
  
  
  RESULTS
  For the differentiation between residual lymphoproliferative activity and inactive residual mass, the highest accuracy was obtained for the signal intensity of residual mass on T2-w-SE compared to pectoralis muscle (94% sensitivity, 80% specificity, likelihood ratios: 4.0 [LR+]; 0.3 [LR-]). The cut-off value of the SI ratio was calculated retrospectively at 1.96 (p > 0.05).
  
  
  CONCLUSIONS
  Differentiation between inactive (fibrotic) and lymphoproliferative (active) residual mediastinal mass is possible by MR imaging using as parameter the size reduction after therapy and the signal intensity on T2-w-SE in comparison to pectoralis muscle. Thus study suggests an additional value using the SI ratio for the differentiation.
authors.affiliation: Klinik für Strahlenheilkunde, Charité Campus Virchow Klinikum, Medizinische Fakultät der Humboldt-Universität zu Berlin. stros@charite.de
authors.forename: C
authors.initials: C
authors.lastname: Stroszczynski
authors.forename: N
authors.initials: N
authors.lastname: Hosten
authors.forename: J
authors.initials: J
authors.lastname: Oellinger
authors.forename: G
authors.initials: G
authors.lastname: Spahn
authors.forename: H
authors.initials: H
authors.lastname: Amthauer
authors.forename: R C
authors.initials: RC
authors.lastname: Bittner
authors.forename: J
authors.initials: J
authors.lastname: Hierholzer
authors.forename: W D
authors.initials: WD
authors.lastname: Ludwig
authors.forename: R
authors.initials: R
authors.lastname: Felix
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006689:Hodgkin Disease / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D008279:Magnetic Resonance Imaging; D008297:Male; D008479:Mediastinal Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D008482:Mediastinum / Q000473:pathology; D008875:Middle Aged; D009367:Neoplasm Staging; D018365:Neoplasm, Residual / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D012680:Sensitivity and Specificity; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone